COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Not yet submitted
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Nanofat: a novel therapeutic approach for vocal cord scar
Scientific title
Effect of nanofat injection for vocal cord scar on voice-related quality of life and stroboscopic measures
Secondary ID [1] 300838 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Vocal cord insufficiency 316723 0
vocal cord scar
316807 0
Condition category
Condition code
Surgery 314970 314970 0 0
Surgical techniques
Respiratory 315136 315136 0 0
Other respiratory disorders / diseases

Study type
Description of intervention(s) / exposure
Nanofat involves mechanically emulsifying and filtering harvested fat. The technique does not require the use of a surgical laboratory, proteolytic enzyme reagents, or specialised equipment. Studies have shown nanofat to contain stromal vascular fraction (SVF) - a non-adipocyte, supportive component of harvested fat and contains a complex population of fibroblasts, macrophages, immune regulatory cells, and a high density of adipocyte-derived stem cells (ADSC).

This study will investigate the role of nanofat injection in vocal fold scar. Patients in this arm will either receive up to 1 mL of dexamethasone (4 mg/mL) versus up to 1 mL of nanofat as a superficial sub-epithelial vocal fold injection into the area of scar.

The senior researcher (PP, ENT surgeon) will perform all injections.
All injections would take place at a tertiary hospital setting in an operating theatre under general anaesthetic. Fat is processed on-site to isolate cells. The fat is harvested from the patient (patients' autologous fat). The sieving process will be the same as the technique already described in the literature by Tonnard et al. The harvested fat will be mechanically emulsified by shifting the sample between two 10-mL syringes connected to each other by Luer-Lok connection. The fat then becomes an emulsion after 30 passes. Following the emulsification process, the liquid is filtered for injection. The harvesting process should take no longer than 30 minutes. All injections occur under general anaesthetic and direct microlaryngoscopy. The entire procedure should be completed in one hour. The harvest and intervention administration occurs under the same general anaesthetic.

The dose administered is difficult to be quantified. This is because different patients will have different degrees of vocal cord scar in addition to patient anatomical variation. In addition, it is also difficult to quantify the exact amount of grafted nanofat, because some may extrude from the injection site after removing the needle. The amount injected at the time of the procedure will be recorded by the operator.
Intervention code [1] 317162 0
Treatment: Surgery
Intervention code [2] 317163 0
Treatment: Other
Comparator / control treatment
Researchers will compare nanofat injection for vocal cord scar to steroid injection (dexamethasone 4 mg/mL)
Control group

Primary outcome [1] 323280 0
Patient reported voice-related quality of life measures
(VoiSS and perceived overall voice impairment on VAS)
Timepoint [1] 323280 0
3, 6, and 12 months (primary timepoint) post-injection
Secondary outcome [1] 381416 0
Vibratory properties measured on stroboscopy by a blinded, trained , independent rater
Timepoint [1] 381416 0
post-procedure at 1 week, 3 months, 6 months, 12 months
Secondary outcome [2] 381417 0
Harmonic: noise ratio measured on Phontary Aerodynamic System Measurement tool
Timepoint [2] 381417 0
3, 6, and 12 months from intervention
Secondary outcome [3] 381418 0
phonation threshold pressure measured on Phontary Aerodynamic System Measurement tool
Timepoint [3] 381418 0
3, 6, and 12 months post-procedure
Secondary outcome [4] 381419 0
Subglottic pressure measured on Phontary Aerodynamic System Measurement tool
Timepoint [4] 381419 0
3, 6, and 12 months post-procedure
Secondary outcome [5] 381424 0
Perturbation measured on stroboscopy
Timepoint [5] 381424 0
3, 6, and 12 months post-procedure
Secondary outcome [6] 381425 0
fundamental frequency measured on stroboscopy
Timepoint [6] 381425 0
3, 6, and 12 months post-procedure
Secondary outcome [7] 381426 0
intensity measured on stroboscopy
Timepoint [7] 381426 0
3, 6, and 12 months post-procedure
Secondary outcome [8] 381427 0
s:z ratio measured on stroboscopy
Timepoint [8] 381427 0
3, 6, and 12 months post-procedure

Key inclusion criteria
vocal cord scar
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
evidence of other vocal fold abnormalities (granuloma, polyps, sulcus or other pathology affecting vocal fold vibration), previous history of glottic cancer, previous laser resection of the vocal fold, prior radiotherapy

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 305295 0
Name [1] 305295 0
Monash Health
Address [1] 305295 0
246 Clayton Road,
Clayton VIC 3168
Country [1] 305295 0
Primary sponsor type
Department of Otolaryngology, Monash Health
Department of ENT
823-65 Centre Road
Bentleigh East VIC 3165
Secondary sponsor category [1] 305656 0
Name [1] 305656 0
Address [1] 305656 0
Country [1] 305656 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 305633 0
Monash Health Human Research Ethics Committee
Ethics committee address [1] 305633 0
246 Clayton Road
Clayton VIC 3168
Ethics committee country [1] 305633 0
Date submitted for ethics approval [1] 305633 0
Approval date [1] 305633 0
Ethics approval number [1] 305633 0

Brief summary
Glottic insufficiency can have negative effects on patient quality of life. This condition mainly affects the quality and strength of voice. Glottic insufficiency can be due to vocal fold scar. Autologous fat and steroid injections have been described to manage vocal fold scar, and have been utilised for many years as a valid technique. A new method of processing fat has been described whereby harvested fat can be processed and filtered quickly and efficiently, leaving behind an easily injectable liquid with a high number of stem cells, without requiring long processing times and highly specialised equipment. It is potentially a modern refinement and improvement of a long-standing technique.
The proposed benefit of nanofat supplementation is that the volume of the injected cord is maintained for longer compared to fat grafting alone. due to increased adipocyte survival. It also has anti-fibrotic effects that are favourable in the treatment of vocal fold scar. Patients will be recruited to undergo nanofat injection for both vocal fold scar. Prior to the surgery, patients will fill out questionnaires and have their vocal cords examined via stroboscopy and undergo objective acoustic and aerodynamic assessment. They will then undergo treatment with follow up assessments occurring at multiple timepoints thereafter, as described in our protocol. The effect of nanofat injection will be compared with steroid injections.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 101030 0
Dr Daniel Wong
Address 101030 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101030 0
Phone 101030 0
+61 39928 8799
Fax 101030 0
Email 101030 0
Contact person for public queries
Name 101031 0
Dr Debra Phyland
Address 101031 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101031 0
Phone 101031 0
+61 39928 8799
Fax 101031 0
Email 101031 0
Contact person for scientific queries
Name 101032 0
Dr Paul Paddle
Address 101032 0
Monash Health
Department of ENT
Rear 867 Centre Rd
Bentleigh East 3165 VIC
Country 101032 0
Phone 101032 0
+6139928 8799
Fax 101032 0
Email 101032 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
Ethical approval
How or where can supporting documents be obtained?
Type [1] 7418 0
Ethical approval
Citation [1] 7418 0
Link [1] 7418 0
Email [1] 7418 0
Other [1] 7418 0
Ethical approval is being obtained through the Monash Health Ethics Review Board.
It is currently pending. When approved, this can be attached to this clinical trial supporting documentation.
Attachment [1] 7418 0
Summary results
No Results